Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells
about
The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancerConjugation to a SMAC mimetic potentiates sigma-2 ligand induced tumor cell death in ovarian cancerInducing death in tumor cells: roles of the inhibitor of apoptosis proteins.Trail resistance induces epithelial-mesenchymal transition and enhances invasiveness by suppressing PTEN via miR-221 in breast cancer.Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF-α but not through TRAIL and FasL.microRNA response elements-regulated TRAIL expression shows specific survival-suppressing activity on bladder cancer.IAP antagonists sensitize murine osteosarcoma cells to killing by TNFαA Smac mimetic augments the response of urothelial cancer cells to gemcitabine and cisplatin.p63 expression correlates with sensitivity to the Eg5 inhibitor ZD4877 in bladder cancer cells.TRAIL-mediated signaling in prostate, bladder and renal cancer.BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG.Silencing Livin induces apoptotic and autophagic cell death, increasing chemotherapeutic sensitivity to cisplatin of renal carcinoma cells.CF3DODA-Me induces apoptosis, degrades Sp1, and blocks the transformation phase of the blebbishield emergency program.Inhibitors of apoptosis: clinical implications in cancer.Do we have biomarkers to predict response to neoadjuvant and adjuvant chemotherapy and immunotherapy in bladder cancer?
P2860
Q28468300-8B9B6309-4AC8-4EE8-8EE6-5E09AB16FF23Q33589984-3FDEA05F-9311-4C5E-95ED-75430CD7797FQ33632016-C86FC934-D1F9-4957-B12D-2E8B4856E15EQ33721556-484D7325-B2B4-4C94-B7F4-03002D6E9205Q36056007-6D8614F0-61C8-4717-8A0C-A46B914C21C0Q37151392-1818BAFE-9A1C-4CE6-A229-62A48C52220DQ37376164-75BB3F41-EAF3-4495-8195-73E1750079A6Q37540196-23E5D5CA-3AA4-4C6C-A164-097488D99A9FQ37644499-FF9C454A-2324-48B3-9554-D3CA125661F9Q37889112-06058F92-BE75-4ECD-A53E-F49E71E9DE86Q39156389-C6EBE05E-964D-4605-A0AF-0DC652D30AC5Q39346297-819224E4-48C5-4177-852E-9779DB91B9FEQ46405590-64EA6B8C-538E-4600-85C1-061B5BEE4A3EQ47607136-26404541-E73A-4928-9940-998724E4A6CBQ49246529-13236356-8E13-4549-9E85-492606BC53F3
P2860
Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Smac mimetic reverses resistan ...... human urothelial cancer cells
@ast
Smac mimetic reverses resistan ...... human urothelial cancer cells
@en
type
label
Smac mimetic reverses resistan ...... human urothelial cancer cells
@ast
Smac mimetic reverses resistan ...... human urothelial cancer cells
@en
prefLabel
Smac mimetic reverses resistan ...... human urothelial cancer cells
@ast
Smac mimetic reverses resistan ...... human urothelial cancer cells
@en
P2093
P2860
P356
P1476
Smac mimetic reverses resistan ...... human urothelial cancer cells
@en
P2093
Adam R Metwalli
Ashish M Kamat
David J McConkey
Debasish Sundi
Goodwin Jinesh
Jay B Shah
Laura M Lashinger
Marissa Shrader
Mark McKinlay
Sanaz Khanbolooki
P2860
P304
P356
10.4161/CBT.10.9.13237
P577
2010-11-01T00:00:00Z